P1125: DURABLES RESPONSES ACHIEVED WITH ANTI-CD19 ALLOGENEIC CAR T ALLO-501/501A IN PHASE 1 TRIALS OF AUTOLOGOUS CAR T-NAÏVE PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (R/R LBCL)
Main Authors: | Javier Munoz, Frederick Locke, Lazaros Lekakis, Herbert Eradat, Michael Tees, Sven de Vos, Rajneesh Nath, Don Stevens, Shahbaz Malik, Leslie Popplewell, Mehdi Hamadani, Olalekan Oluwole, Miguel-Angel Perales, David Miklos, Paul Fisher, Lovely Goyal, Lynn Navale, Gregory Kaufman, Kazuharu Kai, Arun Balakumaran, Sattva Neelapu |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-08-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/01.HS9.0000971396.88082.64 |
Similar Items
-
The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL
by: Marion Subklewe, et al.
Published: (2022-05-01) -
Efficacy and safety of bendamustine‐containing bridging therapy in R/R LBCL patients receiving CD19 CAR T‐cells
by: Gloria Iacoboni, et al.
Published: (2024-07-01) -
Design and CFD of the aerodynamic body of nanyang venture V solar car(B501)
by: Khoo, Raymond Rui Xiang.
Published: (2011) -
CAR T-Cell Therapy: Paving the Path to a Brighter Future in LBCL
by: Frederick Locke
Published: (2023-03-01) -
501 algebra questions /
by: 422957 Recco, William
Published: (2002)